【Lymphoma diagnosis and treatment talent construction project】Appeared at the Takeda booth at CIIE to help achieve the goal of "2030 Healthy China"

The 5th China International Import Expo (hereinafter referred to as the "Expo") was grandly
opened at the National Exhibition and Convention Center (Shanghai) from November 5th to 10th.
The high-profile "Lymphoma Diagnosis and Treatment Talent Construction Project" was further kicked off at the Expo, expressing Takeda Pharmaceutical's firm determination
to deepen its efforts in the field of hematological oncology, contribute to the development of China's lymphoma field, and help achieve the goal of "Healthy China 2030".

Facing up to the gap is a long way to go

Project background and objectives

Looking back at the past four CIIE, "openness" is the key word throughout, and the same is true
in the medical community.
With the unremitting efforts of pioneers in the field, lymphoma has entered the era of precision treatment, and the emergence of targeted therapy drugs such as monoclonal antibodies, bispecific antibodies, ADC drugs and cell therapy drugs has greatly improved the cure rate of lymphoma in China
.
However, due to the vast territory of China, compared with European and American countries, there is still a huge gap
in the overall cure rate of lymphoma patients in China.
We have a long
way to go if we are to achieve the Healthy China 2030 goals.

Professor Ma Jun: "In recent years, the progress of immunochemotherapy, targeted therapy and cellular drug therapy has advanced by leaps and bounds, and lymphoma has developed from incurable to curable
.
Nowadays, the clinical cure rate of lymphoma in large medical centers and specialized hospitals can reach 60%-70%¹, close to the level of European and American countries, but in county-level and prefecture-level urban hospitals, the cure rate of lymphoma is only about 37%, and we still have a long
way to go to achieve the 2030 healthy Chinese malignant tumor to increase the clinical cure rate of 15%².
”

Professor Zhu Jun: "Our goal is to build an increasingly professional, dedicated and progressive lymphoma specialist team to serve Chinese lymphoma patients, further improve the clinical cure rate of Chinese lymphoma patients, and achieve the goal
of 'Healthy China 2030'.
" Our purpose is clear and our responsibility is great
.
”

In line with the call of the times, the lymphoma diagnosis and treatment talent construction project sponsored by the Chinese Health Science and Technology Promotion Association has been successfully launched with the cooperation of all parties, which is committed to cultivating lymphoma diagnosis and treatment talents, establishing lymphoma demonstration centers (COE) and lymphoma diagnosis and treatment pathways, helping clinicians improve the level of diagnosis and treatment, improve the cure rate of lymphoma in China, and benefit more Chinese lymphoma patients
.

Answer the call and teach people to fish

Project content and practice

"A strong youth is a strong China", young and middle-aged doctors are the mainstay of the future medical industry, and the talent training of young and middle-aged doctors is the key to
achieving high-quality and sustainable development of lymphoma specialties.
Therefore, Takeda Pharmaceutical has worked with fellow doctors to build an academic exchange platform, improve the diagnosis and treatment level and diagnosis and treatment ability of young and middle-aged doctors, and work together to improve the cure rate of lymphoma patients
.

Professor Song Yuqin: "To convey our diagnosis and treatment norms, views and consciousness, we must provide more learning opportunities for young and middle-aged doctors, build a platform for knowledge exchange and academic display in the field of lymphoma, and promote the dissemination and promotion
of new knowledge, new concepts and new methods in the field of lymphoma.
" ”

Professor Liu Weiping: "Transmit the experience of our large-scale medical centers downward, and work together to ensure that lymphoma patients 'do not leave the county and the province', so that the national lymphoma diagnosis and treatment level has reached a new level
.
" ”

The lymphoma diagnosis and treatment talent construction project jointly promotes the construction and development
of lymphoma diagnosis and treatment talent team through four steps of diagnosis and treatment path, training practice, guidance and evaluation, license issuance, and different forms such as elite speaker special training camp, standardized lecture tour, and multidisciplinary diagnosis and treatment team (MDT) consultation.

Accurate diagnosis, pathology first, the treatment of lymphoma is inseparable from pathological diagnosis, popularize the concept
of CD30 immunohistochemical detection and result interpretation.
At the same time, based on domestic and foreign guidelines such as CSCO, NCCN, ESMO and the "Lymphoma Diagnosis and Treatment Specification" of Peking University Cancer Hospital, the norms and standards
for the diagnosis and treatment path of CD30+ lymphoma (HL, PTCL, etc.
) were established.

*HL: Hodgkin lymphoma; PTCL, peripheral T-cell lymphoma

Go to the Expo together and set sail hand in hand

Project vision and outlook

It is difficult for the lone to rise, easy for the many, and only cooperation is the way
to success in the future.
With the spillover effect of the Expo platform, it will help promote the resource connection, industrial integration and innovation promotion of lymphoma diagnosis and treatment talent construction projects in the medical and health industry, so that more Chinese patients can maximize the benefits
of diagnosis and treatment.

Professor Ma Jun: "The main body of the medical economy is patient-centered
.
'Life first, life above all else' is the goal of our party and government, as well as our doctors, in order to make lymphoma live longer and achieve a higher clinical cure, we strive hard! ”

Professor Zhu Jun: "We must have the courage to move forward, together with the national counterparts, for the Chinese people, for the health of Chinese lymphoma patients, we believe that the promotion of this project will allow our specialists to receive further training, so that the construction of our lymphoma specialty can be further strengthened, and ultimately achieve our goal
.
" We have confidence, we are also well aware of the great responsibility, work together, cheer together and look forward to the future together! ”

The holding of the Expo is a high-quality development in terms of medical economic development; As far as patients are concerned, it is high-quality survival
.
"Patient first" is Takeda's heritage, is deeply embedded in the genes, the smooth launch of the lymphoma diagnosis and treatment talent construction project, will eventually empower the progress of lymphoma diagnosis and treatment in China, meet the unmet needs of Chinese lymphoma patients, and help achieve
the goal of increasing the overall tumor survival rate by 15% in the five-year plan of "Healthy China 2030".
Although there is a long way to go to improve the cure rate of lymphoma in China, we are already on the way
.

References:

1.
Liu, W, Ji, X, Song, Y, et al.
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades.
Cancer Med.
2020; 9: 3765– 3774.
https://doi.
org/10.
1002/cam4.
3037

2.
"Healthy China 2030" Planning Outline.

Approval code: C-APROM/CN/ADCE/0811

Approved: November 2022

For healthcare professionals only